Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share from the same period last year. The company reported quarterly sales of $736.000 thousand which beat the analyst consensus estimate of $179.000 thousand by 311.17 percent.